ONTARGET^®: New Evidence in Total Cardio & Vascular Protection Satellite Symposium Webcast

Monday 19th May 2008

ONTARGET^®: New Evidence in Total Cardio & Vascular Protection Satellite Symposium Webcast

World Cardio Congress (WCC)

The results of the landmark trial ONTARGET^® were released at the American College of Cardiology (ACC) in Chicago in March 2008. 

The results of the ONTARGET^® trial, and explanations of how these results can be used in clinical practice^*, were the subjects of the satellite symposium supported by Boehringer Ingelheim, at the World Congress of Cardiology (WCC) in Buenos Aires on 19th May 2008. 

Experts from Argentina, Brazil, Italy, and Germany came together to present ONTARGET^®: New Evidence in Total Cardio & Vascular Protection, which was chaired by Professor Michael Böhm, one of the principal investigators of the ONTARGET^® trial, and Leopoldo Piegas.  The following presentations are available as webcasts under the respective links:

Opening remarks

Leopoldo Piegas, Brazil

Blood pressure lowering or cardio & vascular protection – what to aim for?

Giuseppe Mancia, Italy

Cardio & vascular protection – the value of an ARB and an ACE inhibitor

Thomas Unger, Germany presented by Ulrich Kintscher, Germany

The ONTARGET^®results

Rafael Diaz, Argentina

Translating ONTARGET^® into clinical practice

Michael Böhm, Germany

Closing remarks

Michael Böhm, Germany

^* Telmisartan is currently only approved for the treatment of hypertension

These webcasts follow the presentations held on occasion of the World Cardio Congress (WCC) 2008 between 18th - 21st May 2008. They are reproduced here for your personal information. Pursuant to our Terms of Use any sort of reproduction or downloading, in total or in part, is prohibited.